سعر جرانيسيترون 1 مجم / مل 1 امبول 2022

Granisetron 1mg/ml 1 amp: granisetron 1 mg/ml solution for intravenous injection, 1 ampoule, by European Egyptian Pharm. Ind.; a 5-HT3 receptor antagonist antiemetic.

• Prevention and treatment of acute nausea and vomiting associated with chemotherapy and radiotherapyPopulation: AdultsMHRA / electronic medicines compendium (emc)
• Prevention and treatment of post-operative nausea and vomitingPopulation: AdultsMHRA / electronic medicines compendium (emc)
• Prevention of delayed nausea and vomiting associated with chemotherapy and radiotherapyPopulation: AdultsMHRA / electronic medicines compendium (emc)

• Very common: headache, constipation. Common: insomnia, diarrhoea, increased transaminases.International label, equivalent formulation · MHRA / electronic medicines compendium (emc)
• Uncommon: hypersensitivity reactions (e.g. anaphylaxis, urticaria), extrapyramidal reactions, serotonin syndrome, QT interval prolongation, rash.International label, equivalent formulation · MHRA / electronic medicines compendium (emc)

• Hypersensitivity to granisetron or to any of the excipients.International label, equivalent formulation · MHRA / electronic medicines compendium (emc)

• Granisetron may reduce lower bowel motility; patients with signs of sub-acute intestinal obstruction should be monitored after administration.International label, equivalent formulation · MHRA / electronic medicines compendium (emc)
• ECG changes including QT prolongation have been reported; use with caution in patients with pre-existing arrhythmias or conduction disorders, cardiac co-morbidities, cardiotoxic chemotherapy and/or electrolyte abnormalities.International label, equivalent formulation · MHRA / electronic medicines compendium (emc)
• Cross-sensitivity between 5-HT3 antagonists (e.g. dolasetron, ondansetron) has been reported.International label, equivalent formulation · MHRA / electronic medicines compendium (emc)

• QT-prolonging and/or arrhythmogenic medicinal productsConcurrent use with drugs known to prolong the QT interval and/or that are arrhythmogenic may lead to clinical consequences.MHRA / electronic medicines compendium (emc)
• Serotonergic medicinal products (SSRIs, SNRIs)Serotonin syndrome has been reported after concomitant use of 5-HT3 antagonists and other serotonergic medicinal products.MHRA / electronic medicines compendium (emc)
• PhenobarbitalHepatic enzyme induction with phenobarbital increased total plasma clearance of granisetron by approximately 25%.MHRA / electronic medicines compendium (emc)

• Limited data in pregnant women; animal studies do not indicate direct or indirect reproductive toxicity. As a precaution, it is preferable to avoid use during pregnancy.International label, equivalent formulation · MHRA / electronic medicines compendium (emc)
• Unknown whether granisetron or its metabolites are excreted in human milk; as a precaution, breastfeeding should not be advised during treatment.International label, equivalent formulation · MHRA / electronic medicines compendium (emc)

English text not available for this section.